-
1
-
-
34447569438
-
Bevacizumab 5 mg/kg can be infused safely over 10 minutes
-
Reidy DL, Chung KY, Timoney JP, et al: Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 25:2691-2695, 2007
-
(2007)
J Clin Oncol
, vol.25
, pp. 2691-2695
-
-
Reidy, D.L.1
Chung, K.Y.2
Timoney, J.P.3
-
2
-
-
0032530342
-
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
-
Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
-
(1998)
Blood
, vol.92
, pp. 1927-1932
-
-
Coiffier, B.1
Haioun, C.2
Ketterer, N.3
-
3
-
-
0242468884
-
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
-
suppl 16
-
Cobleigh MA, Langmuir VK, Sledge GW, et al: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117-124, 2003 (suppl 16)
-
(2003)
Semin Oncol
, vol.30
, pp. 117-124
-
-
Cobleigh, M.A.1
Langmuir, V.K.2
Sledge, G.W.3
-
4
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
-
(2003)
N Engl J Med
, vol.349
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
-
5
-
-
20644432867
-
Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Hainsworth J, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
-
(2005)
J Clin Oncol
, vol.23
, pp. 3502-3508
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Hainsworth, J.3
-
6
-
-
33144475980
-
E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer
-
Presented at the, Orlando, FL, May 13-17
-
Miller KD, Wang M, Gralow J, et al: E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.
-
(2005)
41st Annual Meeting of the American Society of Clinical Oncology
-
-
Miller, K.D.1
Wang, M.2
Gralow, J.3
-
7
-
-
1542289007
-
A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer
-
Cole BF, Gelber RD, Gelber S, et al: A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat 14:111-124, 2004
-
(2004)
J Biopharm Stat
, vol.14
, pp. 111-124
-
-
Cole, B.F.1
Gelber, R.D.2
Gelber, S.3
-
8
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
9
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry M, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2549, 2006
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2549
-
-
Sandler, A.1
Gray, R.2
Perry, M.3
-
10
-
-
34547173930
-
Berenson A: A cancer drug shows promise, at a price that many can't pay
-
Feb 15
-
Berenson A: A cancer drug shows promise, at a price that many can't pay. New York Times, Feb 15, 2006
-
(2006)
New York Times
-
-
-
11
-
-
30944446883
-
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
-
Jain R, Duda D, Clark J, et al: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40, 2006
-
(2006)
Nat Clin Pract Oncol
, vol.3
, pp. 24-40
-
-
Jain, R.1
Duda, D.2
Clark, J.3
|